Newsroom

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Claritev Corporation (“Claritev” or the “Company”) (NYSE:CTEV). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 14, 2026, The Capitol Forum reported that the U.S. Department of Justice’s anti-trust divisio...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against York Space Systems Inc. (“York Space Systems” or the “Company”) (NYSE:YSS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? York Space Systems completed its initial public offering (“IPO”) in January 2026, sellin...

LOS ANGELES & SINGAPORE--(BUSINESS WIRE)--MedTech Innovator Asia Pacific selected 20 top medtech startups for its 2026 APAC Accelerator from 680+ applicants....

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (NASDAQ:ATEC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 5, 2026, Alphatec reported its first quarter 2026 financial results and updated its full-year outlook....

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca...

PARIJS--(BUSINESS WIRE)--Gustave Roussy gaat samenwerken met One Biosciences, een techbio-bedrijf dat single-cell technologie en AI inzet om geavanceerde precisiediagnose te ontwikkelen. De samenwerking is bedoeld om de haalbaarheid en impact aan te tonen van het integreren van single-nucleus transcriptoomanalyse in het zorgtraject van patiënten. Gustave Roussy, Europa’s toonaangevende kankercentrum, gaat met One Biosciences samenwerken om het baanbrekende potentieel te benutten van OneMapTM, d...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis announced the launch of Ustekinumab BS 45 mg Syringe for S.C. Injection「 NIPRO」 in Japan....

SINGAPORE--(BUSINESS WIRE)--The industry-acclaimed annual rankings recognise the top-performing hotels for MICE business, as well as the world’s most coveted meeting destinations...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate to achieve “be...

PARÍS--(BUSINESS WIRE)--Gustave Roussy se ha asociado con One Biosciences, una empresa biotecnológica especializada en inteligencia artificial y enfocada en el desarrollo de diagnósticos avanzados de precisión mediante tecnología unicelular. La colaboración tiene como objetivo seguir demostrando la viabilidad y el impacto de integrar el análisis transcriptómico de núcleos individuales en la atención clínica de los pacientes. Gustave Roussy, el principal centro oncológico de Europa, colaborará c...